Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219635 · ClinicalTrials.gov registry record · Phase 2
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
A Phase 2 study of Ejaculation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT00219635: Completed Phase 2 study of Ejaculation, sponsored by Pfizer.
NCT00219635 is a Phase 2 study of Ejaculation that has completed, run by Pfizer. The registered enrollment target is 138 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219635, a Phase 2 study of Ejaculation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
Assessment of efficacy and safety UK-390,957
Conditions Studied
Interventions
- DRUG UK-390,957
Study Locations (20)
Ontario
- Pfizer Investigational Site - Barrie
- Pfizer Investigational Site - London
- Pfizer Investigational Site - Toronto
Missouri
- Pfizer Investigational Site - Kansas City
- Pfizer Investigational Site - Washington
New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Williamsville
Texas
- Pfizer Investigational Site - Dallas
- Pfizer Investigational Site - Houston
Alabama
- Pfizer Investigational Site - Birmingham
California
- Pfizer Investigational Site - San Bernardino
Louisiana
- Pfizer Investigational Site - Metairie
Massachusetts
- Pfizer Investigational Site - Watertown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00219635 record still lists
NCT00219635 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Ejaculation appearing as the primary indexed condition, and to 1 intervention - of which UK-390,957 is the first listed.
NCT00219635 names 20 study sites across 15 states, led by Ontario, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT00219635 about?
NCT00219635 is a clinical study titled "Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation". Assessment of efficacy and safety UK-390,957
What is the current status of trial NCT00219635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2005-01. Estimated completion is 2005-07.
What conditions does trial NCT00219635 study?
This clinical trial studies the following conditions: Ejaculation.
What interventions are being tested in trial NCT00219635?
The interventions under investigation include: UK-390,957 (DRUG).
Who is sponsoring clinical trial NCT00219635?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219635 being conducted?
This trial has 20 study locations across Alabama, California, Louisiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ejaculation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00219635's enrollment target sits among peer trials
138 525th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia